Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05572424
Other study ID # 2021/600
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 5, 2023
Est. completion date October 2024

Study information

Verified date March 2024
Source Centre Hospitalier Universitaire de Besancon
Contact Claire BALLOT-SCHMIT, MD
Phone 0381219139
Email cballotschmit@chu-besancon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Juvenile Idiopathic Arthritis (JIA) affects joints mobility and leads pain, impacting the practice of physical activities. Adapted Physical Activities are rehabilitation methods increasingly used, but additional studies are needed to define the nature of the physical activity for patients with JIA. The ATHLETIQUE project aims to evaluate the impact of a program integrating APA sessions together with the wearing of a pedometer watch on disease activity of patients with JIA.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion criteria: - Children (boys and girls) aged 6 to 17 years - Children with juvenile idiopathic arthritis (JIA) : oligoarticular, polyarticular, psoriatic or enthesitis-related arthritis, with more than one year of disease progression - Children on stable conventional or biotherapy 3 months prior to inclusion - Children with a computer/tablet/connected phone that allows them to follow adapted physical activities sessions online - If sexually active adolescents, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double barrier method, contraceptive patches) - Signed informed consent to participate indicating that the parent(s) understand the purpose and procedures required for the study and agree(s) that their child(ren) will participate in the study and abide by the requirements and restrictions of the study - Affiliation with a French social security system or beneficiary of such a system. Non-inclusion criteria: - Treatment by intra-articular infiltration less than 1 month old (immobilization required after the procedure and temporary cessation of physical activity unavoidable) - Contraindications to physical activity - Subject unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator - Subject without health insurance - Pregnant adolescent - Subject in the exclusion period of another study or is the "national volunteer register" Exclusion criteria : - Intra-articular infiltration treatment during the 3 months of the adapted physical activity (APA) program (except for the temporomandibular joint) - Change of biotherapy during the 3 months of the APA program if the treatment is ineffective - Physical inability to engage in physical activity, unrelated to JIA, during the 3-month of the APA program

Study Design


Intervention

Other:
Adaptated Physical Activity (APA) + pedometer watch
Adapted physical activities program : 12 weeks, 2 40-minutes sessions per week ( one broadcast live via online video conferencing and other one in autonomy according to a sequence of different personalized exercises defined by the APA's professional). Children are divided into 6 groups. Each session will be broken down into three parts: the warm-up (10mins), the session's corps alternating between five to eight of muscle strengthening, proprioception, and endurance exercises (20mins) and a cool-down with stretching (10mins). The physical activity performed during the sessions will be quantified with a heart rate monitor and the range of 60-70% of the maximum theoretical heart rate for each child will be respected. A pedometer watch will wear during 1 year and will provide the number of steps.

Locations

Country Name City State
France CHU de Besançon Besançon
France Hospices Civils de Lyon Lyon
France Hôpital Nord Franche-Comté Trévenans

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Juvenile Arthritis Disease Activity-27 Score Assesment JADAS-27 score includes 4 components :
number of inflammatory joints among 27 joints identified,
a medical assesment of clinical disease activity with Visual Analogic Scale (from 0 point = worst to 10 points = best),
assesment of assesment of patient's well-being by the patient or a parent with Visual Analogic Scale (froom 0 point = worst to 10 points = best),
sedimentation rate (from 0 to 10).
Week 14
Secondary Juvenile Arthritis Disease Activity-27 Score Assesment JADAS-27 score includes 4 components :
number of inflammatory joints among 27 joints identified,
a medical assesment of clinical disease activity with Visual Analogic Scale (from 0 point = worst to 10 points = best),
assesment of assesment of patient's well-being by the patient or a parent with Visual Analogic Scale (froom 0 point = worst to 10 points = best),
sedimentation rate (from 0 to 10).
Weeks 26 and 50
Secondary Evaluation of the physical activity level The difference of the medium physical activity level is assessed by the continue measures (for 7 days) of the time spent in the MVPA (Moderate to Vigorous Physical Activity) via actimetry (counts/min).
Actimetric measurements will be performed before the start of the intervention to determine a value for V0, at 13 weeks (for V1), at 25 weeks (for V2), and at 49 weeks (for V3)
Weeks 13, 25 and 49
Secondary Evaluation of the physical activity level The difference of the medium physical activity level is assessed by the number of steps estimated by the pedometer watch (only for the experimental group).
Pedometric measurements will be performed throughout the study but collected one week per month to determine a monthly value.
Each day during 50 weeks
Secondary Quantification of the difference in muscle strength By dynamometry (Newton) Weeks 14, 26 and 50
Secondary Evolution of quality of life Difference of the score obtained in the Pediatric Quality of Life (PedsQL) tool. Score out of 100 for children assess and 100 for parents assess. A high score means a reduced quality of life. Weeks 14, 26 and 50
Secondary Evolution of functional capacities Assessment by the questionnaire of the ChildHood Assessment Questionnaire (CHAQ-38) tool. Questionaire's score out of 3, it's a medium of 8 items. A high score means reduced functional capacities. Weeks 14, 26 and 50
Secondary Evolution of pain Assessment by the Visual Analogic Scale (VAS) of the CHAQ-38 tool. VAS are out of 10. A high score means an increased pain. Weeks 14, 26 and 50
Secondary Evolution of fatigue Difference of the score obtained in the PedsQL-Multidimensional Fatigue Scale questionnaire. Score out of 100 for children assess and 100 for parents assess. A high score means a increased fatigue. Weeks 14, 26 and 50
Secondary Assessment of the feasibility of the program Assessment of program participation. Participation is the proportion of subjects who agree to participate in the study among eligible patients. week 2 to 13
Secondary Assessment of the feasibility of the program Assessment of program completion. Completion is the proportion of subjects who complete the program and proportion of subjects who complete the exercise sessions. week 2 to 13
Secondary Assessment of the feasibility of the program Assessment of program adherence. Adherence is the proportion of sessions attended by subjects. week 2 to 13
Secondary Assessment of the feasibility of the program Assessment of program compliance. Compliance is the proportion of prescribed exercise during the session actually performed. week 2 to 13
Secondary Assessment of the feasibility of the program Assessment of pedometer watch wearing time over the duration of the study. week 1 to 50
See also
  Status Clinical Trial Phase
Completed NCT02776735 - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Phase 2
Active, not recruiting NCT03092427 - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) N/A
Not yet recruiting NCT05545098 - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting NCT03833609 - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis N/A
Completed NCT02524340 - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting NCT01434082 - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis N/A
Completed NCT04671524 - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected N/A
Recruiting NCT04167488 - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy N/A
Recruiting NCT04205500 - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis N/A
Terminated NCT01694264 - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Phase 3
Completed NCT02824978 - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Phase 3
Completed NCT03833271 - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary Early Phase 1
Completed NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 1
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT01436019 - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis N/A
Recruiting NCT05609630 - Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Phase 3
Recruiting NCT05696340 - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05436301 - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)